Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

European Journal of Neurology

Volumn 21, Issue 2, 2014, Pages 299-304

  Bozic, C ^a   Subramanyam, M ^a   Richman, S ^a   Plavina, T ^a   Zhang, A ^a   Ticho, B ^a  

^a BIOGEN   (United States)

Author keywords

Anti JCV antibody; Enzyme linked immunosorbent assay; Epidemiology; JC virus; Multiple sclerosis; Prevalence

Indexed keywords

JC VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; AGED; ANTIBODY TITER; ARTICLE; AUSTRALIA; CANADA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE DURATION; EUROPE; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOASSAY; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; SEROEPIDEMIOLOGY; SEROPREVALENCE; SEX DIFFERENCE; TREATMENT DURATION; VERY ELDERLY; YOUNG ADULT;

ANTI-JCV ANTIBODY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; JC VIRUS; MULTIPLE SCLEROSIS; PREVALENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84892475684     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12304     Document Type: Article

References (19)

1. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47.
2. Ferenczy MW, Marshall LJ, Nelson CDS, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012; 25: 471-506.
3. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437.
4. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the Simian polyomavirus SV40. J Med Virol 2003; 71: 115-123.
5. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199: 837-846.
6. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5: e1000363.
7. Antonsson A, Green AC, Mallitt K-A, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 2010; 91: 1849-1853.
8. Matos A, Duque V, Beato S, Poiares da Silva J, Major E, Melico-Silvestre A. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 2010; 82: 494-504.
9. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
10. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
11. Biogen Idec Inc. Medical information website. https://medinfo.biogenidec.com/medinfo (accessed 01/11/2013).
12. Subramanyam M, Plavina T, Simon K, et al. Factors associated with anti-JCV antibody prevalence in a large cohort of natalizumab-treated MS patients. Mult Scler 2010; 16: S38-S39. Oral presentation 138.
13. Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody prevalence in MS patients: baseline results of STRAIFTY-1. Ann Neurol 2011; 70: 742-750.
14. Moiola L, Sangalli F, Martinelli V, et al. Prevalence of anti-JCV antibodies in a cohort of natalizumab-treated multiple sclerosis patients from Italy. Neurology 2011; 76(Suppl. 4): A375. S30.007.
15. Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY-2. Neurology 2012; 78 (Meeting Abstracts 1): S41.002.
16. Warnke C, Dehmel T, Posevitz-Fejfar A, et al. Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler 2012; 18: 1054-1055.
17. Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 2000; 38: 105-109.
18. Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 2009; 4: e4565.
19. Young CA. Factors predisposing to the development of multiple sclerosis. QJM 2011; 104: 383-386.